Biotech Values

[mcbio]

PCSK9—Lots of articles this week on the various programs from several companies/partnerships (but, oddly, no one has posted them). Perhaps it’s time for an iHub survey on which of these compounds will turn out to be best in class.

Comments?

I think this was brought up before: isn't the fact that a biotech with their own PCSK9 candidate (believe it was ALNY) abandoned the drug due to concerns over the FDA and the likelihood of very long and very expensive trials to disprove any safety concerns still a bearish sign for this drug class?